Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Palladium-catalysed construction of butafulvenes.
Huang X, Chen BZ, Li P, Ji DW, Liu J, Zheng H, Yang SN, Hu YC, Wan B, Hu XP, Fu C, Huang Y, Zheng J, Chen QA, Ma S. Huang X, et al. Among authors: yang sn. Nat Chem. 2022 Oct;14(10):1185-1192. doi: 10.1038/s41557-022-01017-9. Epub 2022 Aug 18. Nat Chem. 2022. PMID: 35982234
Nickel-Catalyzed Unsymmetrical Bis-Allylation of Alkynes.
Li Y, Zhang WS, Yang SN, Wang XY, Liu Y, Ji DW, Chen QA. Li Y, et al. Among authors: yang sn. Angew Chem Int Ed Engl. 2023 Apr 17;62(17):e202300036. doi: 10.1002/anie.202300036. Epub 2023 Mar 15. Angew Chem Int Ed Engl. 2023. PMID: 36826223
Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. Cerchietti LC, et al. Among authors: yang sn. Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02957-0. Online ahead of print. Nat Med. 2024. PMID: 38570701 No abstract available.
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Pan QZ, Zhao JJ, Liu L, Zhang DS, Wang LP, Hu WW, Weng DS, Xu X, Li YZ, Tang Y, Zhang WH, Li JY, Zheng X, Wang QJ, Li YQ, Xiang T, Zhou L, Yang SN, Wu C, Huang RX, He J, Du WJ, Chen LJ, Wu YN, Xu B, Shen Q, Zhang Y, Jiang JT, Ren XB, Xia JC. Pan QZ, et al. Among authors: yang sn. Signal Transduct Target Ther. 2024 Apr 3;9(1):79. doi: 10.1038/s41392-024-01788-2. Signal Transduct Target Ther. 2024. PMID: 38565886 Free PMC article. Clinical Trial.
446 results